Browse > Article
http://dx.doi.org/10.6114/jkood.2020.33.3.099

A Proposal and Considerations for Treatment Approaches of Psoriasis  

Kang, Dong-Won (Department of Ophthalmology, Otolaryngology and Dermatology of Korean Medicine, College of Korean Medicine, Kyung Hee University)
Han, Chang-Yi (Department of Ophthalmology, Otolaryngology and Dermatology of Korean Medicine, College of Korean Medicine, Kyung Hee University)
Kim, Jun-Dong (Department of Ophthalmology, Otolaryngology and Dermatology of Korean Medicine, College of Korean Medicine, Kyung Hee University)
Kim, Kyu-Seok (Department of Ophthalmology, Otolaryngology and Dermatology of Korean Medicine, College of Korean Medicine, Kyung Hee University)
Kim, Yoon-Bum (Department of Ophthalmology, Otolaryngology and Dermatology of Korean Medicine, College of Korean Medicine, Kyung Hee University)
Publication Information
The Journal of Korean Medicine Ophthalmology and Otolaryngology and Dermatology / v.33, no.3, 2020 , pp. 99-114 More about this Journal
Abstract
Objectives : To investigate treatment approaches of psoriasis, and to provide universal and holistic standards to assist in optimizing patient care and future research. Methods : Review articles of psoriasis regarding pathophysiology, risk factor or treatment were searched from Pubmed (January 2016 to June 2020). Treatment approaches were investigated based on the searched articles. Additional data collecting was done for further discussion by searching Pubmed and Google scholar with keywords relevant to the approaches, and the relevant references of articles retrieved were manually inspected to be included. Results : Modalities to directly regulate the relevant helper T cell or inflammatory cytokines can constitute the treatment approaches of psoriasis. Modalities to treat gastrointestinal tract inflammation, to correct metabolic syndrome and to improve epidermal lipid abnormality via whole body lipid metabolism can also constitute the treatment approaches of psoriasis. Probable adverse effects of long term use of western medication should be addressed carefully, and alleviating the hazards of western medication can be a treatment approach of psoriasis. Conclusion : Treatment of psoriasis should take account of systemic aspects such as gastrointestinal tract and lipid metabolism. Treatment approaches of psoriasis established on the pathophysiological basis can serve as universal standards.
Keywords
Psoriasis; Korean Medicine; Inflammation; Lipid Metabolism; Metabolic Syndrome; Skin Barrier;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Kural BV, Orem A, Cimsit G, Yandi YE, Calapoglu M. Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant- antioxidant system in patients with psoriasis. Clinica chimica acta. 2003;328(1-2):71-82.   DOI
2 Mallbris L, Granath F, Hamsten A, Stahle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol. 2006;54(4):614-21.   DOI
3 Orem A, Cimsit G, Deger O, Orem C, Vanizor B. The significance of autoantibodies against oxidatively modified low-density lipoprotein (LDL) in patients with psoriasis. Clinica chimica acta. 1999;284(1):81-8.   DOI
4 Pietrzak A, Jastrzebska I, Krasowska D, Chodorowska G, Tabarkiewicz J, Tomasiewicz K, et al. Serum pancreatic lipase [EC 3.1. 1.3] activity, serum lipid profile and peripheral blood dendritic cell populations in normolipidemic males with psoriasis. J Mol Catal. 2006;40(3-4):144-54.   DOI
5 Piskin S, Gurkok F, Ekuklu G, Senol M. Serum lipid levels in psoriasis. Yonsei Med J. 2003;44(1):24-6.   DOI
6 Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F. Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta. 2001;303(1-2):33-9.   DOI
7 Tekin NS, Tekin IO, Barut F, Sipahi EY. Accumulation of oxidized low-density lipoprotein in psoriatic skin and changes of plasma lipid levels in psoriatic patients. Mediators Inflamm. 2007;2007:78454.
8 Hadas E, Bozek A, Jarzab J. Impact of phototherapy on selected lipid profile indices in psoriatic patients allowing. Postepy Dermatol Alergol. 2007;24(5):215.
9 Reynoso-von Drateln C, Martinez-Abundis E, Balcazar-Munoz BR, Bustos-Saldana R, Gonzalez-Ortiz M. Lipid profile, insulin secretion, and insulin sensitivity in psoriasis. J Am Acad Dermatol. 2003;48(6):882-5.   DOI
10 The Society of Korean Dermatology. Textbook of Dermatology. 6th ed. Seoul: Daehan Med. 2015:299, 867-91.
11 Kamiya K, Kishimoto M, Sugai J, Komine M, Ohtsuki M. Risk Factors for the Development of Psoriasis. Int J Mol Sci. 2019;20(18):4347.   DOI
12 Koppe SW. Obesity and the liver: nonalcoholic fatty liver disease. Transl Res. 2014;164(4):312-22.   DOI
13 Abedini R, Salehi M, Lajevardi V, Beygi S. Patients with psoriasis are at a higher risk of developing nonalcoholic fatty liver disease. Clin Exp Dermatol. 2015;40(7):722-7.   DOI
14 Gisondi P, Targher G, Zoppini G, Girolomoni G. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009;51(4):758-64.   DOI
15 van der Voort EA, Koehler EM, Dowlatshahi EA, Hofman A, Stricker BH, Janssen HL, et al. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: Results from a population-based study. J Am Acad Dermatol. 2014;70(3):517-24.   DOI
16 Carrascosa JM, Vilavella M, Garcia-Doval I, Carretero G, Vanaclocha F, Dauden E, et al. Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry. J Eur Acad Dermatol Venereol. 2014;28(7):907-14.   DOI
17 Boehncke WH, Boehncke S, Tobin AM, Kirby B. The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011;20(4):303-7.   DOI
18 Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, et al. Psoriasis and comorbid diseases: Implications for management. J Am Acad Dermatol. 2017;76(3):393-403.   DOI
19 Gelfand JM, Yeung H. Metabolic syndrome in patients with psoriatic disease. J Rheumatol Suppl. 2012;89:24-8.   DOI
20 Ganzetti G, Campanati A, Offidani A. Non-alcoholic fatty liver disease and psoriasis: So far, so near. World J Hepatol. 2015;7(3):315-26.   DOI
21 Lizzul PF, Aphale A, Malaviya R, Sun Y, Masud S, Dombrovskiy V, et al. Differential expression of phosphorylated $NF-{\kappa}B$/RelA in normal and psoriatic epidermis and downregulation of $NF-{\kappa}B$ in response to treatment with etanercept. J Invest Dermatol. 2005;124(6):1275-83.   DOI
22 Lee JY, Kang S, Park JS, Jo SJ. Prevalence of Psoriasis in Korea: A Population-Based Epidemiological Study Using the Korean National Health Insurance Database. Ann Dermatol. 2017;29(6):761-7.   DOI
23 Greb JE, Goldminz AM, Elder JT, Lebwohl MG, Gladman DD, Wu JJ, et al. Psoriasis. Nat Rev Dis Primers. 2016;2:16082.   DOI
24 Kim BH, Kim KI, Kang SH, Park JG, Kang DW, Nam HJ, et al. Explanation and Elaboration of the Clinical Trial Guidelines for Psoriasis Using Herbal Medicine. J Korean Med Ophthalmol Otolaryngol Dermatol. 2018;31(2):40-59.   DOI
25 Grozdev I, Korman N, Tsankov N. Psoriasis as a systemic disease. Clin Dermatol. 2014;32(3):343-50.   DOI
26 Canavese M, Altruda F, Ruzicka T, Schauber J. Vascular endothelial growth factor (VEGF) in the pathogenesis of psoriasis-a possible target for novel therapies? J Dermatol Sci. 2010;58(3):171-6.   DOI
27 Luan L, Han S, Wang H, Liu X. Down-regulation of the Th1, Th17, and Th22 pathways due to anti-TNF-${\alpha}$ treatment in psoriasis. Int Immunopharmacol. 2015;29(2):278-84.   DOI
28 Lynde CW, Poulin Y, Vender R, Bourcier M, Khalil S. Interleukin 17A: toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol. 2014;71(1):141-50.   DOI
29 Lin Y, See L, Huang Y, Chi C, Hui RC. Comparison of indirubin concentrations in indigo naturalis ointment for psoriasis treatment: a randomized, double-blind, dosage-controlled trial. British Journal of Dermatology. 2018;178(1):124-31.   DOI
30 Frieder J, Ryan C. Psoriasis and cardiovascular disorders. G Ital Dermatol Venereol. 2016;151(6):678-93.
31 Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of$TNF-{\alpha}$, IFN-${\gamma}$, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. 2005;2005(5):273-9.   DOI
32 Hong SI. The Effects of Saengkankunbi-tang and Its Composition on Free Fatty Acid-Induced Lipotoxicity in HepG2 Cell. J Int Korean Med. 2013;34(1):14-30.
33 Choi ES, Kim HY, Cho YH, Jang EG, Woo HJ, Kim YC. A Case Report of Adolescent Nonalcoholic Fatty Liver Disease (NAFLD) with Severe Obesity. J Int Korean Med. 2015:89-95.
34 Sin SM, Cha JH, Kim GT, Byun SH, Ko HK. Saenggangeonbi-tang's effest on metabolic syndrome. J Int Korean Med. 2008:65-70.
35 Kang KR, Baek SH, Lee MS, Jung YJ, Choi AR, Shin JS. A Male Nonalcoholic Steatohepatitis (NASH) Patient Diagnosed with Moderate Fibrosis using Fibroscan-a Case Report. J Int Korean Med. 2015:120-6.
36 Swindell WR, Johnston A, Carbajal S, Han G, Wohn C, Lu J, et al. Genome-wide expression profiling of five mouse models identifies similarities and differences with human psoriasis. PLoS One. 2011;6(4):e18266.   DOI
37 Nakajima K, Terao M, Takaishi M, Kataoka S, Goto-Inoue N, Setou M, et al. Barrier abnormality due to ceramide deficiency leads to psoriasiform inflammation in a mouse model. J Invest Dermatol. 2013;133(11):2555-65.   DOI
38 Ye L, Lv C, Man G, Song S, Elias PM, Man M. Abnormal epidermal barrier recovery in uninvolved skin supports the notion of an epidermal pathogenesis of psoriasis. J Invest Dermatol. 2014;134(11):2843.   DOI
39 Yan Y, Liu W, Andres P, Pernin C, Chantalat L, Briantais P, et al. Exploratory clinical trial to evaluate the efficacy of a topical traditional Chinese herbal medicine in psoriasis vulgaris. Evidence-Based Complementary and Alternative Medicine. 2015;2015:719641.   DOI
40 Lin Y, Chang Y, Hui RC, See L, Chang C, Yang C, et al. A Chinese herb, indigo naturalis, extracted in oil (Lindioil) used topically to treat psoriatic nails: a randomized clinical trial. Jama Dermatology. 2015;151(6):672-4.   DOI
41 Lu C, Liu H, Jin X, Chen Y, Liang C, Qiu F, et al. Herbal components of a novel formula PSORI-CM02 interdependently suppress allograft rejection and induce CD8+ CD122+ PD-1+ regulatory T cells. Frontiers in pharmacology. 2018;9:88.   DOI
42 Cheng H, Wu Y, Wang Q, Song M, Wu J, Chen D, et al. Clinical efficacy and IL-17 targeting mechanism of Indigo naturalis as a topical agent in moderate psoriasis. BMC complementary and alternative medicine. 2017;17(1):1-11.   DOI
43 Wu M, Deng Y, Li S, Chen Y, Guo D, Jin X, et al. The immunoregulatory effects of traditional Chinese medicine on psoriasis via its action on interleukin: advances and considerations. The American journal of Chinese medicine. 2018;46(04):739-50.   DOI
44 Wang D, Gu J, Zhu W, Luo F, Chen L, Xu X, et al. PDTCM: a systems pharmacology platform of traditional Chinese medicine for psoriasis. Annals of medicine. 2017;49(8):652-60.   DOI
45 Sun W, Gao Y, Yu X, Yuan Y, Yi J, Zhang Z, et al. 'Psoriasis 1'reduces psoriasis-like skin inflammation by inhibiting the VDR-mediated nuclear $NF-{\kappa}B$ and STAT signaling pathways. Molecular medicine reports. 2018;18(3):2733-43.
46 Eppinga H, Konstantinov SR, Peppelenbosch MP, Thio HB. The microbiome and psoriatic arthritis. Curr Rheumatol Rep. 2014;16(3):407.   DOI
47 Khyshiktuev BS, Falko EV. Alterations in the parameters of lipid metabolism in different biological objects in psoriatic patients during exacerbation and remission. Vestn Dermatol Venerol. 2005;6:40-3.
48 Hong KK, Cho HR, Ju WC, Cho YH, Kim NI. A study on altered expression of serine palmitoyltransferase and ceramidase in psoriatic skin lesion. J Korean Med Sci. 2007;22(5):862-7.   DOI
49 Motta S, Monti M, Sesana S, Mellesi L, Ghidoni R, Caputo R. Abnormality of water barrier function in psoriasis. Role of ceramide fractions. Arch Dermatol. 1994;130(4):452-6.   DOI
50 Ansidei V, Binazzi M, Cantelmi A, Gaiti A, Porcellati G. Phospholipid involvement in psoriatic epidermis. Ital J Biochem. 1981;30(1):40-5.
51 Khyshiktuev BS, Karavaeva TM, Fal'ko EV. Variability of quantitative changes in short-chain fatty acids in serum and epidermis in psoriasis. Klin Lab Diagn. 2008(8):22-4.
52 Maxfield FR, Tabas I. Role of cholesterol and lipid organization in disease. Nature. 2005;438(7068):612-21.   DOI
53 Melton JL, Wertz PW, Swartzendruber DC, Downing DT. Effects of essential fatty acid deficiency on epidermal O-acylsphingolipids and transepidermal water loss in young pigs. BBA-Mol Cell Biol L. 1987;921(2):191-7.
54 van Schaik FD, Oldenburg B, Hart AR, Siersema PD, Lindgren S, Grip O, et al. Serological markers predict inflammatory bowel disease years before the diagnosis. Gut. 2013;62(5):683-8.   DOI
55 Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, et al. Psoriasis and comorbid diseases: Epidemiology. J Am Acad Dermatol. 2017;76(3):377-90.   DOI
56 Huang BL, Chandra S, Shih DQ. Skin manifestations of inflammatory bowel disease. Front Physiol. 2012;3:13.   DOI
57 Cohen AD, Dreiher J, Birkenfeld S. Psoriasis associated with ulcerative colitis and Crohn's disease. J Eur Acad Dermatol Venereol. 2009;23(5):561-5.   DOI
58 Hansen HS, Jensen B. Essential function of linoleic acid esterified in acylglucosylceramide and acylceramide in maintaining the epidermal water permeability barrier. Evidence from feeding studies with oleate, linoleate, arachidonate, columbinate and ${\alpha}$-linolenate. BBA-Mol Cell Biol L. 1985;834(3):357-63.
59 Elias PM, Brown BE, Ziboh VA. The permeability barrier in essential fatty acid deficiency: evidence for a direct role for linoleic acid in barrier function. J Invest Dermatol. 1980;74(4):230-3.   DOI
60 Pietrzak D, Pietrzak A, Krasowska D, Borzecki A, Franciszkiewicz-Pietrzak K, Polkowska-Pruszynska B, et al. Digestive system in psoriasis: an update. Arch Dermatol Res. 2017;309(9):679-93.   DOI
61 Li WQ, Han JL, Chan AT, Qureshi AA. Psoriasis, psoriatic arthritis and increased risk of incident Crohn's disease in US women. Ann Rheum Dis. 2013;72(7):1200-5.   DOI
62 Juzlova K, Votrubova J, Dzambova M, Gopfertova D, Hercogova J, Smerhovsky Z. Gastrointestinal comorbidities in patients with psoriasis in the Czech Republic: The results of 189 patients with psoriasis and 378 controls. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016;160(1):100-5.   DOI
63 Scarpa R, Manguso F, D'Arienzo A, D'Armiento FP, Astarita C, Mazzacca G, et al. Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms. J Rheumatol. 2000;27(5):1241-6.
64 Michaelsson G, Kraaz W, Hagforsen E, Pihl-Lundin I, Loof L, Scheynius A. The skin and the gut in psoriasis: the number of mast cells and CD3+ lymphocytes is increased in non-involved skin and correlated to the number of intraepithelial lymphocytes and mast cells in the duodenum. Acta Derm Venereol. 1997;77(5):343-6.
65 Feingold KR, Man MQ, Menon GK, Cho SS, Brown BE, Elias PM. Cholesterol synthesis is required for cutaneous barrier function in mice. J Clin Invest. 1990;86(5):1738-45.   DOI
66 Tsuji K, Mitsutake S, Ishikawa J, Takagi Y, Akiyama M, Shimizu H, et al. Dietary glucosylceramide improves skin barrier function in hairless mice. J Dermatol Sci. 2006;44(2):101-7.   DOI
67 Holleran WM, Man M, Gao WN, Menon GK, Elias P, Feingold K. Sphingolipids are required for mammalian epidermal barrier function. Inhibition of sphingolipid synthesis delays barrier recovery after acute perturbation. J Clin Invest. 1991;88(4):1338-45.   DOI
68 Mao-Qiang M, Elias PM, Feingold KR. Fatty acids are required for epidermal permeability barrier function. J Clin Invest. 1993;92(2):791-8.   DOI
69 Nikkari T, Schreibman PH, Ahrens Jr E. Isotope kinetics of human skin cholesterol secretion. J Exp Med. 1975;141(3):620-34.   DOI
70 Bhattacharyya AK, Connor WE, Spector AA. Excretion of sterols from the skin of normal and hypercholesterolemic humans: Implications for sterol balance studies. J Clin Invest. 1972;51(8):2060-70.   DOI
71 Kalantzis A, Marshman Z, Falconer DT, Morgan PR, Odell EW. Oral effects of low-dose methotrexate treatment. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;100(1):52-62.   DOI
72 Atkins D, Furuta GT. Mucosal immunology, eosinophilic esophagitis, and other intestinal inflammatory diseases. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S255-61.   DOI
73 Mowat AM, Agace WW. Regional specialization within the intestinal immune system. Nat Rev Immunol. 2014;14(10):667-85.   DOI
74 Grubauer G, Feingold KR, Elias PM. Relationship of epidermal lipogenesis to cutaneous barrier function. J Lipid Res. 1987;28(6):746-52.   DOI
75 Menon GK, Feingold KR, Moser AH, Brown BE, Elias PM. De novo sterologenesis in the skin. II. Regulation by cutaneous barrier requirements. J Lipid Res. 1985;26(4):418-27.   DOI
76 Song HJ, Park CJ, Kim TY, Choe YB, Lee SJ, Kim NI, et al. The Clinical Profile of Patients with Psoriasis in Korea: A Nationwide Cross-Sectional Study (EPIPSODE). Ann Dermatol. 2017;29(4):462-70.   DOI
77 Itani S, Arabi A, Harb D, Hamzeh D, Kibbi AG. High prevalence of metabolic syndrome in patients with psoriasis in Lebanon: a prospective study. Int J Dermatol. 2016;55(4):390-5.   DOI
78 Pietrzak A, Michalak-Stoma A, Chodorowska G, Szepietowski JC. Lipid disturbances in psoriasis: an update. Mediators Inflamm. 2010;2010:535612.   DOI
79 Singh S, Young P, Armstrong AW. An update on psoriasis and metabolic syndrome: A meta-analysis of observational studies. PLoS One. 2017;12(7):e0181039.   DOI
80 Langan SM, Seminara NM, Shin DB, Troxel AB, Kimmel SE, Mehta NN, et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol. 2012;132(3 Pt 1):556-62.   DOI
81 Parodi A, Aste N, Calvieri C, Cantoresi F, Carlesimo M, Fabbri P, et al. Metabolic syndrome prevalence in psoriasis: a cross-sectional study in the Italian population. Am J Clin Dermatol. 2014;15(4):371-7.   DOI
82 Karoli R, Fatima J, Shukla V, Dhillon KS, Khanduri S, Maini S, et al. A study of cardio-metabolic risk profile in patients with psoriasis. J Assoc Physicians India. 2013;61(11):798-803.
83 Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006;298(7):321-8.   DOI
84 Sikora M, Chrabaszcz M, Maciejewski C, Zaremba M, Waskiel A, Olszewska M, et al. Intestinal barrier integrity in patients with plaque psoriasis. J Dermatol. 2018;45(12):1468-70.   DOI
85 Lee IW, Choi HY, Lee JH, Park SD, Kim SM, Ku SK, et al. Saeng-Kankunbi-Tang (生肝健脾湯) protects liver against oxidative damage through activation of ERK/Nrf2 pathway. Chin J Integr Med. 2016;22(8):619-28.   DOI
86 Tichy M, Hercogova J. Manifestation of Crohn's disease in a young woman during the course of treatment for severe form of chronic plaque psoriasis with etanercept. Dermatol Ther. 2014;27(4):211-4.   DOI
87 Guerra I, Algaba A, Perez-Calle JL, Chaparro M, Marin-Jimenez I, Garcia-Castellanos R, et al. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases. J Crohns Colitis. 2012;6(5):518-23.   DOI
88 Cullen G, Kroshinsky D, Cheifetz AS, Korzenik JR. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther. 2011;34(11-12):1318-27.   DOI
89 Hong ND, Kim JW, Kim BW, Shon JG. Studies on the Efficacy of the Combined Preparation of Crude Drugs (VII): Effects of Saengkankunbi-Tang on the Liver Tissue Recovery. Korean J Pharmacog. 1982;13(2):70-8.
90 Kim JY, Kim YC, Lee JH, Woo HJ. The Effects of Saengkankunbi-tang on Proliferation, Apoptosis and Cell Signaling Pathways of HepG2 Cells. J Int Korean Med. 2006;27(1):149-65.
91 Hong ND, Kim JW, Kim BW, Shon JG. Studies on the Efficacy of the Combined Preparation of Crude Drugs (VI): Effect of Saengkankunbi-Tang on Activities of the Liver Enzyme, Protein Contents and the Excretory Action of Bile Juice in the Serum of CCl4-intoxicated Rabbits. Korean J Pharmacog. 1982;13(1):33-8.
92 Amin T, Saied E, Abdou SH. Atherosclerotic risk in psoriasis. Journal of Pan Arab League of Dermatologists. 2005;16(2):39-45.
93 Al-Mutairi N, Nour T. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial. Expert Opin Biol Ther. 2014;14(6):749-56.   DOI
94 Snekvik I, Nilsen TIL, Romundstad PR, Saunes M. Metabolic syndrome and risk of incident psoriasis: prospective data from the HUNT Study, Norway. Br J Dermatol. 2019;180(1):94-9.   DOI
95 Akhyani M, Ehsani AH, Robati RM, Robati AM. The lipid profile in psoriasis: a controlled study. J Eur Acad Dermatol Venereol. 2007;21(10):1330-2.   DOI
96 Bajaj DR, Mahesar SM, Devrajani BR, Iqbal MP. Lipid profile in patients with psoriasis presenting at Liaquat University Hospital Hyderabad. J Pak Med Assoc. 2009;59(8):512.
97 Cohen AD, Sherf M, Vidavsky L, Vardy DA, Shapiro J, Meyerovitch J. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology. 2008;216(2):152-5.   DOI
98 Coimbra S, Oliveira H, Reis F, Belo L, Rocha S, Quintanilha A, et al. Circulating levels of adiponectin, oxidized LDL and C-reactive protein in Portuguese patients with psoriasis vulgaris, according to body mass index, severity and duration of the disease. J Dermatol Sci. 2009;55(3):202-4.   DOI
99 Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol. 2007;157(1):68-73.   DOI
100 Javidi Z, Meibodi NT, Nahidi Y. Serum lipids abnormalities and psoriasis. Indian J Dermatol. 2007;52(2):89.   DOI